India’s Department of Pharmaceuticals Holds Up NPPA Pricing Decision for Acetazolamide

Sun Pharma’s request to change the price cap set by India’s National Pharmaceutical Pricing Authority (NPPA) for acetazolamide 500 mg, a drug for glaucoma, has been rejected by the Department of Pharmaceuticals (DoP). The manufacturer had argued that the NPPA had based its pricing decision based on the 2021 price cap for the 250 mg capsule, not the increased price set in 2022.

According to the company, “By not considering the ceiling price already notified in March 2022 by NPPA, well before the date of the company application, the company is at a loss of Rs. 0.89 per capsule, which cannot be ignored.”

To read more, click here.

(Source: Medical Dialogues, February 20^th, 2023)